The lawsuit against Bristol Myers Squibb over a scuttled Contingent Value Rights (CVR) dividend linked to its $74 billion Celgene merger is getting more specifics.…
The lawsuit against Bristol Myers Squibb over a scuttled Contingent Value Rights (CVR) dividend linked to its $74 billion Celgene merger is getting more specifics.…